The Department of Hematology, Changhai Hospital affiliated to Shanghai Second Military Medical University, is a specialized hematology center of the whole army. It has a modern laminar flow ward and an advanced clinical nursing system. The research in leukemia diagnosis and treatment, autologous bone marrow and peripheral blood stem cell transplantation has reached the international advanced level. The second and third cases of unrelated peripheral blood hematopoietic stem cell transplantation in China successfully treated leukemia. Carry out research on the diagnosis and treatment of acute severe and extremely severe radiation sickness. The main clinical features are the diagnosis and treatment of leukemia, lymphoma and other malignant hematological diseases, the related research and application of hematopoietic stem cell transplantation, the gene therapy research of hematological diseases, the pathophysiological research of erythrocyte membrane and enzymes, and the diagnosis and treatment of hemolytic anemia, which ranks at the advanced level in China. ? 1962 established the hematology department of internal medicine, 1978 established the hematology department, and 1979 approved the General Logistics Department of the People's Liberation Army as the blood center of the whole army. At present, it is the authorized point of master's degree and doctor's degree in medicine, the discipline of national drug clinical research base, the discipline of post-doctoral mobile station in clinical medicine of the Second Military Medical University, and one of the key disciplines of Changhai Hospital. At present, there are 46 medical teaching and scientific research technicians, including 2 professors and chief physicians, 4 associate professors and deputy chief physicians, researchers and deputy chief technicians 1 person, and intermediate titles1person. Most medical teachers and researchers have doctoral or master's degrees. At present, there are postdoctoral, doctoral and graduate students 1 1 person. There are 34 expanded beds and 5 advanced aseptic fluidized beds; The professional laboratory covers an area of 440M2, and has modern clinical and experimental equipment such as laminar aseptic laboratory, programmed cryostat, computer cytopathology influence system, blood cell separator, gel imaging system, fluorescence microscope, fluorescence inverted microscope and clinical magnetic immune cell separator. The annual average number of outpatients is more than 6,500, and the number of inpatients is about 500. It can be used for treating benign and malignant hematological diseases such as acute and chronic leukemia, lymphoma and anemia. Entrusted by the General Logistics Department, seven specialized courses and advanced specialized courses in hematology were held in the whole army, each for 10-3 years, which trained a group of hematology professionals for the army and local governments, including many well-known hematology scholars in China. The new medical technologies developed in this discipline over the years mainly include: 1, which is used for hematopoietic stem cell transplantation for malignant diseases and acute radiation sickness, such as fetal liver cell transplantation, semi-contract allogeneic bone marrow transplantation, autologous and allogeneic peripheral blood stem cell transplantation, parent-child peripheral blood stem cell transplantation, unrelated bone marrow transplantation and CD34+ cell transplantation; 2. Clinical study of hemophilia B gene therapy (the first case in the world); 3. Establish a relatively complete method for the determination of erythrocyte enzymopathy and erythrocyte membrane disease and the diagnosis of difficult hemolytic anemia; 4. Comprehensive treatment of acute leukemia and malignant lymphoma; 5. Diagnosis of difficult blood diseases. Since 1980, it has undertaken more than 50 scientific research projects such as the National "863" High-tech Project Fund, the National Outstanding Talents Fund (Cooperation), the National Natural Science Fund and the Key Projects Fund of the PLA. Since 1982, it has won more than 20 fourth prizes for military scientific and technological progress, including the second prize for national invention, the third prize for national scientific and technological progress, the first prize for scientific and technological progress in Shanghai and the military, and the second prize for military scientific and technological progress and medical achievements. Professor E, Professor Lin and Professor Min Bihe, who have served as the directors of our department, enjoy a high reputation in the field of hematology inside and outside the military and have made important contributions to the construction and development of this discipline. The current director, Professor Wang Jianmin, chief physician, doctoral supervisor, the training target of "100 outstanding academic leaders across the century" in Shanghai health system, and the "scientific and technological star" in the General Logistics Department of the People's Liberation Army. Professor Xu Xiaoping, deputy director, deputy chief physician, tutor for master students. As mankind enters the 2 1 century, all the colleagues in the hematology department of Changhai Hospital will, as always, adhere to the principle of taking clinic as the center, taking teaching as the foundation and scientific research as the driving force, cooperate sincerely with colleagues in the domestic hematology field, serve patients wholeheartedly, and make our due contribution to the development of hematology in China. At present, the clinical characteristics and research directions of the undergraduate course mainly include the diagnosis and comprehensive treatment of malignant hematological diseases such as leukemia and malignant lymphoma, the related research and clinical application of hematopoietic stem cell transplantation, the gene therapy research of hematological diseases, erythrocyte membrane and enzymes. Hematopoietic stem cell transplantation for malignant hematological diseases in Changhai Hospital. Since 1982, when fetal liver cell transplantation was first carried out in China, hematopoietic stem cell transplantation has made rapid progress. 1986 for autologous and allogeneic bone marrow transplantation in the treatment of malignant hematological diseases. 1990, 2 cases of acute radiation sickness were treated with HLA mismatched bone marrow transplantation, 1 case was successful, which was the first case in China. 1995 for autologous and allogeneic peripheral blood stem cell transplantation, 1997 for allogeneic peripheral blood stem cell transplantation. At present, 5 patients have been admitted. A 20-year-old patient was diagnosed as acute lymphoblastic leukemia and received allogeneic peripheral blood stem cell transplantation in our hospital. The donor is his sister, and HLA is a bit incompatible. After transplantation, severe acute graft-versus-host disease occurred. This is the first HLA-incompatible peripheral blood stem cell transplantation in China. 1998 took the lead in carrying out allogeneic peripheral blood stem cell transplantation with incomplete HLA matching between parents and children in Shanghai, and achieved success. In the same year, unrelated donor bone marrow transplantation was carried out to treat malignant hematopathy, and 6 cases were treated. Ding Jian, a student of Fudan University who was widely concerned by the media, received unrelated donor bone marrow transplantation in our hospital for chronic myeloid leukemia. At present, the hematopoietic function has basically recovered and the situation is good. Purified autologous peripheral blood CD34+ cells were transplanted to treat malignant hematological diseases. This world advanced technology was carried out by our institute on 1999. And successfully treat multiple myeloma, lymphoma and other diseases. Jiefang Daily, Wen Wei Po, Health News, People's Liberation Army Daily and other media rushed to report, which had a wide social impact. This year, our hospital carried out allogeneic peripheral blood stem cell transplantation from unrelated donors, and 2 patients were successfully transplanted. Hematopoietic stem cell transplantation not only treats acute and diffuse leukemia, but also treats myeloma, lymphoma, acute aplastic anemia and other diseases. Up to now, 80 cases of hematopoietic stem cell transplantation and 40 cases of allogeneic peripheral blood stem cell transplantation have been carried out, with a success rate of over 90% and a two-year survival rate of about 75%, reaching the international level.